期刊文献+

白血病细胞疫苗研究进展 被引量:1

下载PDF
导出
摘要 主动免疫治疗在延长白血病患者化疗后无病生存期以及消除微小残留病变中发挥着重要作用,其基本原理是用肿瘤抗原激发机体免疫系统消灭残存的肿瘤。白血病细胞疫苗以及负载白血病抗原的树突状细胞疫苗可诱导机体产生特异性免疫应答,在小鼠体内已显示了抗肿瘤效应,并已有部分进入了Ⅰ/Ⅱ期临床试验阶段,具有较好的应用前景,值得进一步研究。
作者 胡刚 李扬秋
出处 《国外医学(内科学分册)》 2006年第11期501-504,共4页 Foreign Medical Sciences(Section of Internal Medicine)
  • 相关文献

参考文献20

  • 1Pinilla-lbarz J, Cathcart K, Korontsvit T, et al.[J]. Blood, 2000,95(5) :1781-1787.
  • 2Borrello IM, Sotomayor EM, [ J ]. Cancer Control,2002,9(2) :138-151,
  • 3李扬秋主编.[M].血液肿瘤免疫治疗学,第1版.人民卫生出版社,2005,54-60.
  • 4Moingeon P, [J]. Vaccine, 2001,19 (11-12) :1305-1326.
  • 5王振义,陈秋生.急性白血病免疫治疗的研究现况和前景[J].中国实验血液学杂志,2005,13(2):169-173. 被引量:12
  • 6Takahashi T. Tanaka Y, Nieda M, et al. [J].Leuk Res, 2003,27 (9) :795-802.
  • 7Zeng Y, Feng H, Graner MW, et al. [ J ]. Blood,2003,101 ( 11 ) :4485-4491.
  • 8Zeng Y, Graner MW, Thompson S, et al. [ J].Blood, 2005,105 ( 5 ) :2016-2022.
  • 9Li M, You S, Ge W, et al. [J]. Chin Med J(Engl), 2003,116( 11 ) : 1655-1661.
  • 10Kalady MF, Onaitis MW, Padilla KM, et al. [ J ].J Surg Res, 2002,105 ( 1 ) : 17-24.

二级参考文献28

  • 1王建祥.急性髓系白血病的化疗[A]..第八次全国血液学学术会议论文汇编[C].北京,2004.第31页.
  • 2Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.Expert Opin Biol Ther, 2001; 1: 893 -901.
  • 3Leopold LH, Berger MS, Feingold J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma, 2002; 2 ( Suppl 1 ): S29- S34.
  • 4Tsimberidou A, Estey F, Cortes J, et al. Gemtuzumab, fiudarabine, cytarbine and cyclosporine in patients with newly newly diagnosed acute myelogenous leukemin or high-risk myelodysplastic syndrome. Cancer, 2003; 97:1481 - 1487.
  • 5LoCoco F, Cimino G, Breccia M, et al. Gentuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 2004; 104: 1995 - 1999.
  • 6Lundin J, Kimby E, Bjorkholm M, et al. Phase Ⅱ trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campth1H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2002; 100: 768 - 773.
  • 7Hillmen P. Advancing therapy for chronic lymphocytic leukemia -the role of rituximab. Semin Oncol, 2004; 31 (Suppl 2): 22 -26.
  • 8Mourad YA, Taher A, Chehal A, et al. Successful treatment of Bcell prolymphocytic leukemia mith monoclonal anti-CD20 antibody.Ann hematol, 2004; 83:319-321.
  • 9Chen J,Zhou JH, Ball ED. Characterization of a new monoclonal antibody 6G7 that recognizes a unique antigen on myeloid and lymphoid cells. J Hematother & Stem Cell Res, 2001; 10:237 -246.
  • 10Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control, 2002; 9: 106 - 113.

共引文献11

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部